In the pharmaceutical industry, data that offers insight into patient behavior and industry experience are precious commodities. As part of the Express Scripts family of companies, UBC is a vehicle for pharmaceutical and biotech manufacturers to capitalize on a wealth of industry expertise.
The past twelve months have brought change, and with it, new opportunity. In our last blog post of 2013, we want to take a moment to reflect on our accomplishments and share with our readers some highlights from this past year:
Much like patient populations, successful launches come in all sizes. Congratulations go to Regeneron this quarter on the success of the EYLEA® (aflibercept) Injection, which was approved by the FDA in November 2011 and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), the key cause of blindness in the elderly.
YOUR patients are OUR patients -- and your products help them live healthier lives. As Express Scripts and Medco move forward together as one company, including HealthBridge Pharma & Biotech, United BioSource, CuraScript, and Accredo, we will continue to provide best-in-class services so your patients can access the therapies they need.
Throughout the country today, as more and more people learn of Express Scripts' merger with Medco, something important will happen. Patients will visit their doctors and receive their prescriptions. That's important because it happens every day! Today, however, the doctors you work with may have questions about the merger and how it may affect their patients and their practice.
Beginning today, Express Scripts and Medco move forward together as one company, including CuraScript, Accredo, HealthBridge Pharma & Biotech, and United BioSource Corporation. The combination of our experience, years of service in the healthcare industry, and knowledge of your products and patients creates an unparalleled commitment to you and the future of healthcare.